FinTech
UBS clients help transform the biotech industry through the UBS Oncology Impact Fund
Orna Therapeutics, founded by MPM and its affiliate BioImpact Capital with funding from the UBS Oncology Impact Fund, announces USD 3.75 billion collaboration to develop the next generation of vaccines 100% of the USD 471 million raised for the fund came from UBS Global Wealth Management clients Transaction may revolutionize…
Continue Reading
Subscribe to unlock the full article and access premium financial content.
Click here to read the full story: UBS